These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35805050)

  • 21. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
    Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
    Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-Center Outcomes of Epstein-Barr Virus DNAemia in Adult Solid Organ Transplant Recipients.
    Dong SW; Blair BM; Alonso CD
    J Transplant; 2024; 2024():5598324. PubMed ID: 38283325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.
    Quinlan SC; Pfeiffer RM; Morton LM; Engels EA
    Am J Hematol; 2011 Feb; 86(2):206-9. PubMed ID: 21264909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM; Adams W; Grim SA; Clark NM; Edwards L; Layden JE
    J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
    Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY
    Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
    J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient.
    Lee C; Vincentelli H; Visuri J; Knight S; Ploeg R
    Cureus; 2021 Sep; 13(9):e18134. PubMed ID: 34567913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
    Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
    Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database.
    Lee CC; Hsu TC; Kuo CC; Liu MA; Abdelfattah AM; Chang CN; Yao M; Li CC; Wu KH; Chen TC; Gau JP; Wang PN; Liu YC; Chiou LW; Lee MY; Li SS; Chao TY; Jou ST; Chang HH
    Oncologist; 2021 Nov; 26(11):e2034-e2041. PubMed ID: 34506688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying the patient at risk for post-transplant lymphoproliferative disorder.
    Cockfield SM
    Transpl Infect Dis; 2001 Jun; 3(2):70-8. PubMed ID: 11395972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
    Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
    Malouf MA; Chhajed PN; Hopkins P; Plit M; Turner J; Glanville AR
    J Heart Lung Transplant; 2002 May; 21(5):547-54. PubMed ID: 11983544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.
    Tai R; Tirumani SH; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH
    Br J Radiol; 2015 Aug; 88(1052):20140861. PubMed ID: 25989696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
    Hyun H; Park E; Cho M; Min SI; Ha J; Kang HJ; Shin HY; Ha IS; Cheong HI; Ahn YH; Kang HG
    J Korean Med Sci; 2019 Aug; 34(30):e203. PubMed ID: 31373185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.